Ozempic maker Novo Nordisk says it has developed a compound that’s shown to be a one-two punch for appetite suppression and ...

The push to develop the first oral GLP-1 receptor drug for obesity is heating up, as four phase 3 drugs race to become the first approved oral treatment for obesity, Global Data reported Dec. 2. Here ...

Ozempic and other GLP-1 agonist medications have risen in popularity over the last few years due to their touted blood sugar management and weight-loss effects. However, some supp ...

GLP-1 RAs to assist with weight loss have exploded in popularity. Researchers are working to identify which patients will ...

Allurion's new program uses artificial intelligence guidance to help patients adhere to a well-rounded diet and exercise ...

A collection of studies presented at a recent American Heart Association (AHA) conference has confirmed the heart health benefits provided by the new anti-obesity drugs, semaglutide and tirzepatide, ...

Takers of GLP-1 are reportedly going on a "holiday pause" to enjoy meal centric family celebrations. Here, an MD breaks down ...

Brand companies who own GLP-1 products have been pushing the Food and Drug Administration (FDA) to limit their compounding. On August 28, 2024, ...

News of Biden administration's proposal to require Medicare and Medicaid health insurance to cover weight loss drugs could trigger private employers to do the same.

At ObesityWeek 2024, researchers presented the latest data on treatment regimens for chronic weight management, including GLP ...

In 2024, coverage for obesity drugs increased to 44% among employers with 500 or more workers, compared to 41% last year, the ...